Having trouble accessing articles? Reset your cache.

NIBR Shanghai exits discovery to refocus on clinical development, local collaborations

Novartis AG doesn't have a better solution than its multnational peers for how to fruitfully leverage discovery science in China. The pharma is closing down discovery operations at its Shanghai-based Novartis Institutes for BioMedical Research (NIBR) in favor

Read the full 381 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers